Bronchiolitis primary prevention: Difference between revisions
Created page with "{{CMG}} {{Bronchiolitis}} ==Overview== ==Prevention== In general, prevention of bronchiolitis relies on measures to reduce the spread of the viruses that cause respiratory in..." |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{CMG}} | {{CMG}} | ||
{{Bronchiolitis}} | {{Bronchiolitis}} | ||
==Overview== | ==Overview== | ||
In general, prevention of bronchiolitis relies on measures to reduce the spread of the viruses that cause respiratory infections (that is, handwashing, and avoiding exposure to those symptomatic with respiratory infections). | In general, prevention of bronchiolitis relies on measures to reduce the spread of the viruses that cause respiratory infections (that is, handwashing, and avoiding exposure to those symptomatic with respiratory infections). | ||
Line 10: | Line 10: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Needs content]] | |||
[[Category:Viral diseases]] | |||
[[Category:Inflammations]] | |||
[[Category:Pediatrics]] | |||
[[Category:Pulmonology]] | |||
[[Category:Disease]] | |||
{{WH}} | |||
{{WS}} |
Revision as of 21:11, 4 December 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Bronchiolitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Bronchiolitis primary prevention On the Web |
American Roentgen Ray Society Images of Bronchiolitis primary prevention |
Risk calculators and risk factors for Bronchiolitis primary prevention |
Overview
In general, prevention of bronchiolitis relies on measures to reduce the spread of the viruses that cause respiratory infections (that is, handwashing, and avoiding exposure to those symptomatic with respiratory infections).
Premature infants, and others with certain majory cardiac and respiratory disorders, can receive passive immunization with Palivizumab (a monoclonal antibody against RSV). This form of passive immunization therapy requires monthly injections every winter. Whether it could benefit infants with lung problems secondary to muscular dystrophies and other vulnerable groups is currently unknown.